Susan S Ellenberg

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi Evaluating the safety of new vaccines: summary of a workshop
    Susan S Ellenberg
    Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, MD, USA
    Am J Public Health 95:800-7. 2005
  2. ncbi Pediatric deaths reported after vaccination: the utility of information obtained from parents
    Linda E Silvers
    U S Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Biostatistics and Epidemiology, Rockville, Maryland 20855, USA
    Am J Prev Med 22:170-6. 2002
  3. ncbi Monitoring the safety of vaccines: assessing the risks
    Susan S Ellenberg
    Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, Maryland, USA
    Drug Saf 25:145-52. 2002
  4. ncbi Analytical, practical and regulatory issues in prevention studies
    Susan S Ellenberg
    Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, FDA, 1401 Rockville Pike, HFM 210, Rockville, MD 20852, USA
    Stat Med 23:297-303. 2004
  5. ncbi Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis?
    Baruch A Brody
    Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas, USA
    J Bone Miner Res 18:1105-9. 2003
  6. ncbi Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001
    Weigong Zhou
    Epidemic Intelligence Service Program, Epidemiology Program Office, CDC, USA
    MMWR Surveill Summ 52:1-24. 2003
  7. ncbi A global perspective on vaccine safety and public health: the Global Advisory Committee on Vaccine Safety
    Peter I Folb
    Medical Research Council, PO Box 19070, Tygerberg 7505, Cape Town, South Africa
    Am J Public Health 94:1926-31. 2004

Collaborators

  • L E Silvers
  • C Siegrist
  • Paul Henri Lambert
  • T J John
  • R T Chen
  • R Ball
  • John D Clemens
  • Peter I Folb
  • Baruch A Brody
  • Weigong Zhou
  • Heinz J Schmitt
  • Ewa Bernatowska
  • C Patrick Farrington
  • David Salisbury
  • Omala Wimalaratne
  • Noni E MacDonald
  • Heinz-J Schmitt
  • Elizabeth Miller
  • Alex N O Dodoo
  • Robert P Heaney
  • Vitali Pool
  • Robert P Pless
  • Roseanne English-Bullard
  • John K Iskander
  • Robert J Levine
  • M Miles Braun
  • Penina Haber
  • Nancy Dickey
  • Gina Mootrey
  • Charles Weijer
  • Robert P Wise
  • Ruth B Purtilo

Detail Information

Publications7

  1. ncbi Evaluating the safety of new vaccines: summary of a workshop
    Susan S Ellenberg
    Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, MD, USA
    Am J Public Health 95:800-7. 2005
    ..The advantages and disadvantages of conducting large controlled trials before licensure or widespread use of a new vaccine were discussed. We summarize these presentations and discussions...
  2. ncbi Pediatric deaths reported after vaccination: the utility of information obtained from parents
    Linda E Silvers
    U S Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Biostatistics and Epidemiology, Rockville, Maryland 20855, USA
    Am J Prev Med 22:170-6. 2002
    ..This investigation explored whether routinely interviewing parents for follow-up of VAERS pediatric deaths would provide additional information important to vaccine safety...
  3. ncbi Monitoring the safety of vaccines: assessing the risks
    Susan S Ellenberg
    Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, Maryland, USA
    Drug Saf 25:145-52. 2002
    ....
  4. ncbi Analytical, practical and regulatory issues in prevention studies
    Susan S Ellenberg
    Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, FDA, 1401 Rockville Pike, HFM 210, Rockville, MD 20852, USA
    Stat Med 23:297-303. 2004
    ....
  5. ncbi Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis?
    Baruch A Brody
    Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas, USA
    J Bone Miner Res 18:1105-9. 2003
    ..Active control trials are permissible and desirable if they can be designed and conducted in ways that overcome the interpretive difficulties often associated with such trials...
  6. ncbi Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001
    Weigong Zhou
    Epidemic Intelligence Service Program, Epidemiology Program Office, CDC, USA
    MMWR Surveill Summ 52:1-24. 2003
    ..This knowledge facilitates improvement in the safety of vaccines and the vaccination process...
  7. ncbi A global perspective on vaccine safety and public health: the Global Advisory Committee on Vaccine Safety
    Peter I Folb
    Medical Research Council, PO Box 19070, Tygerberg 7505, Cape Town, South Africa
    Am J Public Health 94:1926-31. 2004
    ....